## Saturday, September 27

### Risk Factors and Pathology

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30 – 9:15</td>
<td>Chronic allograft dysfunction (CAD) in pediatric renal transplant recipients&lt;br&gt;Chairs: Josep Grinyó, Spain and Elias David-Neto, Brazil&lt;br&gt;Speaker: William Harmon, USA</td>
<td>Michelangelo Ballroom 2</td>
</tr>
<tr>
<td>9:15 - 9:45</td>
<td>Coffee and Networking Break</td>
<td>Michelangelo Ballroom 1 &amp; Foyer</td>
</tr>
<tr>
<td>9:45 – 12:00</td>
<td>Risk factors of CAD&lt;br&gt;Chairs: Josep Grinyó, Spain and Elias David-Neto, Brazil&lt;br&gt;■ Epidemiology of CAD&lt;br&gt;Speaker: Fernando Cosio, USA&lt;br&gt;■ Chronic allograft nephropathy, rejection and renal function&lt;br&gt;Speaker: Johan de Fijter, The Netherlands&lt;br&gt;■ The metabolic syndrome and CAD&lt;br&gt;Speaker: Armando Torres, Spain&lt;br&gt;■ Infectious causes of chronic allograft dysfunction&lt;br&gt;Speaker: Paul Sweny, UK&lt;br&gt;■ Round Table Discussion&lt;br&gt;Moderated by session chairs, Elias David-Neto, Brazil and the four speakers above</td>
<td>Michelangelo Ballroom 2</td>
</tr>
<tr>
<td>12:00 – 12:15</td>
<td>Session Break</td>
<td>Michelangelo Ballroom 1 &amp; Foyer</td>
</tr>
<tr>
<td>12:15 – 13:15</td>
<td>BMS Symposium: Rational approaches to managing chronic allograft dysfunction in the 21st century&lt;br&gt;Chair: Flavio Vincenti, USA</td>
<td>Michelangelo Ballroom 2</td>
</tr>
<tr>
<td>13:15 – 14:00</td>
<td>Lunch and Networking Break</td>
<td>Michelangelo Ballroom 1 &amp; Foyer</td>
</tr>
<tr>
<td>14:00 – 14:30</td>
<td>Poster Session and Discussion</td>
<td>Michelangelo Ballroom 1</td>
</tr>
<tr>
<td>14:30 – 16:00</td>
<td>Pathology of chronic allograft dysfunction (CAD)&lt;br&gt;Chairs: Manuel Pascual, Switzerland and Emilio Ramos, USA&lt;br&gt;■ Optimal classification criteria&lt;br&gt;Speaker: Lorraine Racusen, USA&lt;br&gt;■ Pathology of CAD, a new look&lt;br&gt;Speaker: Heinz Regele, Austria&lt;br&gt;■ Lessons from Protocol Biopsies: The Westmead Experience&lt;br&gt;Speaker: Jeremy Chapman, Australia&lt;br&gt;■ Lessons from protocol biopsies 2&lt;br&gt;Speaker: David Rush, Canada</td>
<td>Michelangelo Ballroom 2</td>
</tr>
<tr>
<td>16:00 – 16:30</td>
<td>Coffee and Networking Break</td>
<td>Michelangelo Ballroom 1 &amp; Foyer</td>
</tr>
<tr>
<td>16:30 – 18:00</td>
<td>Clinical Workshop: Infections and CAD&lt;br&gt;Chairs: Emilio Ramos, USA and Adel Bakr, Egypt&lt;br&gt;■ Polyoma&lt;br&gt;Speaker: Emilio Ramos, USA&lt;br&gt;■ Hepatitis C virus infection in kidney transplant patients&lt;br&gt;Speaker: Manuel Pascual, Switzerland&lt;br&gt;■ Post transplantation infection and CAD&lt;br&gt;Speaker: Adel Bakr, Egypt</td>
<td>Michelangelo Ballroom 2</td>
</tr>
</tbody>
</table>
### Sunday, September 28

#### Therapy and Management

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:15 – 9:45</td>
<td><strong>Coffee and Networking Break</strong></td>
<td>Michelangelo Ballroom 1 &amp; Foyer</td>
</tr>
<tr>
<td>9:45 – 12:00</td>
<td><strong>Management of chronic allograft dysfunction</strong>&lt;br&gt;Chairs: Marcelo Cantarovich, <em>Canada</em> and Giuseppe Remuzzi, <em>Italy</em>&lt;br&gt;- Immune monitoring to guide immunosuppressive therapy&lt;br&gt;Speaker: Roslyn Mannon, <em>USA</em>&lt;br&gt;- Optimal immunosuppression protocols to avoid CAD&lt;br&gt;Speaker: Josep Grinyó, <em>Spain</em>&lt;br&gt;- Interventions to interrupt CAD&lt;br&gt;Speaker: Marcelo Cantarovich, <em>Canada</em>&lt;br&gt;- Non-immune interventions: BP, lipids&lt;br&gt;Speaker: Giuseppe Remuzzi, <em>Italy</em>&lt;br&gt;- Round Table Discussion: Optimal immunosuppression for CAD&lt;br&gt;Moderated by: the session chairs, speakers; Emilio Ramos, <em>USA</em> and Nancy Bridges, <em>USA</em></td>
<td>Michelangelo Ballroom 2</td>
</tr>
<tr>
<td>12:00 – 13:00</td>
<td>Lunch and Networking Break</td>
<td>Michelangelo Ballroom 1 &amp; Foyer</td>
</tr>
<tr>
<td>13:00 – 14:30</td>
<td><strong>Free Communications</strong>&lt;br&gt;Chairs: Giuseppe Remuzzi, <em>Italy</em> and Josep Grinyó, <em>Spain</em></td>
<td>Michelangelo Ballroom 2</td>
</tr>
</tbody>
</table>
Reza Abdi, MD
USA

Reza Abdi is currently the Assistant Professor of Medicine at Harvard Medical School. He underwent his medical residency at the Taleghani University Hospital, Tehran, Iran from 1990-1993. He then took up his Nephrology Fellowship at Bocage University Hospital, Dijon, France for three years. From here he spent two years undergoing his Transplantation Fellowship, Johns Hopkins Hospital, Baltimore followed by his Internal Medicine Residency at the University of Pennsylvania Health System in Philadelphia. In 1999 he spent a further three years at Brigham and Women’s Hospital in Boston on his Nephrology Fellowship. In 2002 he took up the position of Instructor in Medicine at Harvard Medical School where he now holds his current position of Assistant Professor of Medicine.

He has written the following selection of peer-reviewed publications (in chronological order).


Mohamed Adel Bakr, MD
Egypt

Mohamed Adel Bakr is a Senior Consultant of Nephrology and Urology at the Nephrology Center in Mansoura, Egypt. His career started in 1978 with transplant activity and he has been actively involved in presentations and publications on the subject over the years. He is an experienced speaker and was a WHO Consultant in Nephrology from 1997-1999. He also spent three years in the UK as a lecturer in the master of nephrology. Among his achievements he was awarded the national encouragement prize for medical science in 1999.

Enver Akalin, MD
USA

Dr. Akalin earned his medical degree at the Ege University Medical School in Turkey. He did his residency in Internal Medicine and a fellowship in Clinical Transplantation at the Emory University School of Medicine. He did a research fellowship at the Renal Division of Brigham and Women’s Hospital of Harvard Medical School followed by a clinical fellowship in the Renal Division of Boston University Medical School. Dr. Akalin joined the Mount Sinai School of Medicine as a Faculty in 2000 and now serves as a Medical Director of Kidney and Pancreas Transplant Program.

Dr. Akalin’s research interest is to understand the mechanisms of acute and chronic allograft rejection by investigating the gene expression profiles of transplant kidney biopsies by microarrays. His other main research interest is kidney transplantation in sensitized recipients by using desensitization protocols with intravenous immune globulin (IVIG) and plasmapheresis. He studies the mechanisms of IVIG and its effect on donor-specific antibodies.

David M. Briscoe, MD
USA

Dr. Briscoe is currently Associate Professor of Pediatrics at Harvard Medical School, Boston, USA. He received his MB.Bch. from the Royal College of Surgeons, Ireland in 1982. He trained in Pediatrics in Dublin, Ireland and at the University of Colorado Health Sciences Center, in Denver, USA, and in Pediatric Nephrology at the Children’s Hospital, Boston. His research commenced at the Brigham and Women’s Hospital in Boston, and he subsequently established a vascular biology and transplantation research program at the Children’s Hospital Boston. Dr. Briscoe
has served on national advisory committees related to the promotion of transplantation research, and he is a member of numerous societies including the National Honors Society, the American Society for Clinical Investigation. He served as a Board Member of the American Society of Transplantation (AST), and is a past recipient of the AST Basic Science Investigator Award. He also serves on National Institutes of Health Study sections pertaining to vascular biology and transplantation. Dr Briscoe is also the Program Director of the Training Program in Nephrology at the Children’s Hospital, Boston.

Marcelo Cantarovich, MD  
Canada

Marcelo Cantarovich, graduated in Medicine from the University of Buenos Aires, Argentina, in 1980. He worked as a transplant coordinator at Argentina Transplant (CUCAI) from 1977 to 1982. He completed his residency in Internal Medicine in Buenos Aires, and a fellowship in nephrology and transplantation at Université Paris-Sud in Paris, France from 1984 to 1988. He is Associate Professor of Medicine, Medical Director of the Kidney and Pancreas Transplant Program and Associate Director of the Multi-Organ Transplant Program, Royal Victoria Hospital, McGill University Health Center, Montréal, Québec, Canada. His clinical interest is in multi-organ transplantation. His research focuses on immunopharmacology and on renal protection strategies in renal and non-renal transplant patients. He has published over 85 manuscripts in peer-reviewed journals. He is a member of the Editorial Board of Transplantation and Clinical Journal of the American Society of Transplantation. He has chaired the Clinical Trials Committee of the American Society of Transplantation in 2006, the 2007 Key Opinion leader symposium organized by The Transplantation Society in Montréal and the 2008 scientific meeting of the Canadian Society of Transplantation. Dr. M. Cantarovich is a board member and Treasurer of the Canadian Society of Transplantation and member of the Council of The Transplantation Society.

Anil Chandraker, MD  
USA

Anil Chandraker is the Medical Director of Kidney Transplantation at Brigham and Women’s Hospital. He received his medical degree from Glasgow University and trained at numerous hospitals throughout the UK and at Brigham and Women’s Hospital/Harvard Medical School where he was trained a research/clinical fellow in nephrology. He has been on faculty at the Brigham and Women’s Hospital/Harvard Medical School since 1999. Dr. Chandraker’s laboratory research focuses on chronic allograft rejection with an emphasis on the role of negative T cell costimulatory pathways. His clinical research interests include anemia and BK nephropathy in renal transplant recipients as well as studying the effects of development of anti-HLA antibodies post transplantation. His research is currently funded through grants from the NIH, DCI and National Kidney Foundation. He has over 100 publications and is an active member of the American Society of Transplantation, the American Society of Nephrology and the Transplantation Society.

Jeremy Chapman, MD, PhD  
Australia

Professor Jeremy Chapman is a renal physician with a special interest in transplantation. He is Director of Acute Interventional Medicine (SWAHS) and Renal Services at Westmead Hospital, Consultant Medical Director to the NSW Australian Red Cross Blood Service Tissue Typing Laboratory and Chairman of the Australian Bone Marrow Donor Registry, the Australian Cord Blood Bank Network and the Cognate Committee on Organ and Tissue Donation and Transplantation and Past President of the Transplantation Society of Australia and New Zealand. On a global level he is President Elect of The Transplantation Society, Immediate Past President of the World Marrow Donor Association and Chair of the Global Alliance for Transplantation. Professor Chapman’s clinical work is in renal medicine, transplantation of kidney and pancreas and diabetic renal disease and islet transplantation, while he is currently pursuing research interests in transplantation, tissue typing and xenotransplantation. Professor Chapman is actively involved in the academic field having over 250 clinical papers to his name. He is a Professor at the University of Sydney. He is a Fellow of the Royal College of Physicians in the United Kingdom and a Fellow of the Royal Australasian College of Physicians.
Robert B. Colvin, M.D.
USA

Robert B. Colvin is the Benjamin Castleman Distinguished Professor of Pathology and former Chief of Pathology at MGH. Dr. Colvin has held NIH grants since 1975, receiving a MERIT award from the NIH in 1987. His research interests include renal pathology, particularly transplantation immunopathology. His current interest is in humoral rejection, tolerance, xenotransplantation and mechanisms of chronic graft injury. He has trained more than 30 research and clinical fellows, many of whom have become medical leaders themselves. He has authored more than 400 publications and books. Dr. Colvin is a member of many scientific boards, including the International Academy of Pathology, the American Society for Investigative Pathology, American Association of Immunologists, American Society of Nephrology, The Transplantation Society, Massachusetts Medical Society, College of American Pathology (Fellow), American Society of Clinical Pathology, the Association of Pathology Chairs and the Board of Trustees of the Roche Organ Transplant Research Foundation.

Fernando G. Cosio, MD
USA

Fernando G. Cosio is currently a Professor at the Mayo Clinic Medical School in Rochester, Minnesota since 2002. where he has been a consultant in the Nephrology & Hypertension division. He studied medicine at the Universidad de Valladolid in Spain and did his Residency and Nephrology fellowship at the University of Minnesota from 1974-1980. From 1982- 2002 he was an Instructor-Professor at The Ohio State University. He was Board certified in Internal Medicine (1978) and Nephrology (1982). His research interest includes; Kidney allograft survival, Long term kidney recipient survival and Glomerulonephritis. His current grant funding includes the following:


Prof. Dr. Johan W. de Fijter, MD, PhD
The Netherlands

Hans de Fijter, MD, PhD was trained in internal medicine and nephrology at Leiden University in the Netherlands. Currently he is professor of Nephrology and director of the Kidney and Pancreas Transplant Program at Leiden University Medical Center. Professor de Fijter is the President of the Netherlands Transplantation Society and Chairman of the Eurotransplant Kidney Advisory Committee. Research interests include clinical immunosuppression, pharmacokinetics, (subclinical) acute rejection, calcineurin inhibitor-related nephrotoxicity and chronic allograft nephropathy) with an emphasis on novel biomarkers at the tissue, cellular and molecular level (histology, histochemistry, molecular biology and metabolomics).
Anthony Dorling, MD  
UK
Dr. Anthony Dorling qualified in Medicine from the University of London in 1987 and did general medical training in the South East of England, gaining his membership of the Royal College of Physicians in 1990. He did his PhD under the supervision of Robert Lechler at the Royal Postgraduate Medical School, before embarking on specialist training in Nephrology in 1995. He was appointed Senior Lecturer in Immunology at Imperial College and honorary consultant nephrologist at the Hammersmith Hospital in 2001. He was awarded fellowship of the Royal College of Physicians in 2005 and became a member of the Association of Physicians of Great Britain and Ireland in 2007.
His early research interests were in xenotransplantation, out of which grew his interest in coagulation proteases and the role of protease activated receptors in inflammation and immunity, especially in transplantation. He maintains an interest in xenotransplantation, alongside an active clinical research programme investigating mechanisms and novel treatment regimes in chronic allograft rejection. He is an associate editor of the international journals 'American Journal of Transplantation' and 'Xenotransplantation' and a member of the International Xenotransplantation Association Committee.

Josep Grinyó, MD, PhD  
Spain
Josep Grinyó, MD, PhD, is the Chief of Nephrology at the University Hospital of Bellvitge and Full Professor of Medicine at the University of Barcelona, Department of Medicine. Dr. Grinyó’s research work on renal transplantation has been focused on immunosuppression, ischemia-reperfusion injury and chronic allograft damage in the clinical setting and in experimental animal models.
Dr. Grinyó is Associate Editor of the American Journal of Transplantation, Current Opinion in Transplantation and Nephrology Dialysis and Transplantation, and member of the editorial boards of Clinical Journal of the American Society Nephrology and Transplantation. Dr. Grinyó has been widely published, having authored or co-authored over 250 articles in journal publications. Dr. Grinyó has also participated in more than 150 international lectureships, seminar invitations and visiting professorships throughout his career.

William Harmon, MD  
USA
William Harmon, M.D. is currently the Director of the Nephrology Division of Children’s Hospital Boston and Professor of Pediatrics at Harvard Medical School.
Dr. Harmon received his M.D. degree from Case Western Reserve University in 1971 and received his residency and fellowship training at Children’s Hospital Boston. After the completion of that training he was appointed the first pediatric director of the division’s dialysis unit and later the kidney transplant program. He was named the division chief in 1987 where he continues to lead the largest pediatric nephrology training program in the country.
Dr. Harmon’s research interests include innovative approaches to immunosuppression for children with organ transplants. He has directed several NIH-sponsored multi-center clinical trials that include mechanistic studies during the past decade. He is currently chairman of the steering committee of the Clinical Trials of Organ Transplantation in Children (CTOTC) of NIAID. He is also President of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) which has conducted over a dozen clinical trials and has published more than 100 articles in the scientific literature. He is the pediatric consultant to the Scientific Registry of Transplant Recipients and serves on the Board of Directors of the Organ Procurement and Transplant Network of DHHS.
Dr. Harmon has served as chairman of the Board of Directors of the New England Organ Bank, as President of the American Society of Transplantation and as a member of the Board of Directors of the International Pediatric Transplantation Association. He was the only pediatrician appointed to the initial Advisory Committee for Organ Transplantation (ACOT) of DHHS.
Dr. Harmon is one of the three editors of Pediatric Nephrology, the major textbook of the discipline, and of Pediatric Organ Transplantation.
Robert Lechler, MD, PhD
UK

He qualified in Medicine in Manchester in 1975. Thereafter, he undertook four years of junior hospital doctor training in general medicine and nephrology before embarking on a PhD in transplantation immunology at the Royal Postgraduate Medical School. Following the PhD, he returned to full-time clinical work for two years and completed his scientific training at the National Institutes of Health in Bethesda, USA. He returned to the UK to a Senior Lecturer Post at the Royal Postgraduate Medical School in 1986 and became Head of the Department of Immunology in 1994. He became Dean of Hammersmith Campus at Imperial College Faculty of Medicine in 2001 and Head of the Division of Medicine in 2003. He moved to King’s College London as Head of the School of Medicine at Guy’s, King’s College and St Thomas’ Hospitals in September 2004 and was appointed Vice Principal (Health) at King’s in October 2005. He continues to direct a research group in transplantation immunology and His research group has three major interests:

1. Defining and exploiting the mechanisms of transplantation tolerance
2. Regulating coagulation as a mechanism to inhibit inflammatory and adaptive immune responses
3. Defining the “fingerprint” of clinical transplantation tolerance

Joren C. Madsen, MD
USA

Dr. Joren C. Madsen is the Director of the MGH Transplant Center, the Section Chief of Cardiac Surgery and the W. Gerald and Patricia R. Austen Distinguished Scholar in Cardiac Surgery at Massachusetts General Hospital. He graduated from Brown University in 1977 and received his medical degree from the University of Massachusetts in 1982. He also holds a doctoral degree in Immunology from Balliol College, Oxford University. His research interests include immune tolerance chronic allograft rejection and the role of innate immunity in organ transplantation.

Roslyn Mannon, MD
USA

Dr. Mannon is Professor of Medicine and Surgery at the University of Alabama, Birmingham in the Division of Nephrology and Director of Research for the Alabama Transplant Center. Dr. Mannon graduated from Duke University Medical School and completed her medical internship, residency, chief residency, and nephrology fellowship at Duke as well. From 2000-2008, she was Medical Director of Transplantation in the Transplantation Branch of NIDDK, a translational research program in transplantation immunology. Dr. Mannon’s academic interests include concurrent studies in clinical and basic transplantation. Her laboratory utilizes small rodent models to understand recipient complications, with a focus on kidney allograft fibrosis, novel targets of chronic allograft injury, and the contribution of BK virus in chronic allograft injury. She has authored or coauthored over 75 articles and reviews on immune monitoring, chronic allograft injury, transplantation complications and tolerance trials. Dr. Mannon is active in professional societies as a Councilor-at-Large for the American Society of Transplantation, serves as an Associate Editor for the American Journal of Transplantation and is on the Post-Graduate and Education Committees of the American Society of Nephrology.

Peter Nickerson, MD
Canada

Dr. Peter Nickerson is a Transplant Nephrologist and Professor of Internal Medicine and Immunology at the University of Manitoba. He is the Medical Director of the Transplant Immunology Laboratory and the Canadian Blood Services Platelet Immunology Laboratory. Dr. Nickerson obtained his MD, Internal Medicine and Nephrology training at the University of Manitoba, followed by a Transplant Research Fellowship at Harvard from 1991 - 1995. His clinical research program is focused on the mechanisms underlying acute and chronic rejection and developing non-invasive techniques for the diagnosis of rejection.
Philip O’Connell, MD
Australia

Dr. O’Connell is Director of Transplantation at the Renal Unit, Westmead Hospital, University of Sydney and is director of the Centre for Transplant and Renal Research, Westmead Millennium Institute. He is also director of Australia’s Clinical Islet Transplant Collaborative and has had a long research commitment to islet transplantation, especially in the field of islet xenotransplantation. His clinical research interests include the pathogenesis of chronic allograft nephropathy, in particular the molecular mechanisms involved in this condition. He is principal investigator in a large collaborative project investigating the genomics of chronic allograft rejection. He is immediate past president of the Transplantation Society of Australia and New Zealand and Secretary/Treasurer of the International Xenotransplant Association. He was chair of the program committee for the Transplantation Society Congress that was held in Sydney in August 2008.

Manuel A. Pascual, MD
Switzerland

Manuel Pascual currently Professor at the Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne was born in 1961 and he received his MD in 1986. He undertook his residency in internal medicine at the University Hospital of Geneva, where he subsequently worked as a postdoctoral research fellow in immunonephrology. From 1993 to 2002, Dr. Pascual worked in the Renal and Transplantation Units at the Massachusetts General Hospital in Boston, and, in 2000, he was appointed Assistant Professor of Medicine at Harvard Medical School in Boston.

In 2003, he returned to Switzerland as Chief of the newly established Transplantation Center at the CHUV and he became Full Professor at the Faculty of Biology and Medicine from the University of Lausanne, Switzerland. His major research interests have been the humoral mechanisms of allograft rejection and the prevention and treatment of chronic allograft nephropathy.

He is the recipient of a 2003 Clinical Science Award of the American Society of Transplantation. He is author or co-author of more than 150 publications in the fields of immunology, nephrology and transplantation.

Lorraine Racusen MD
USA

She is currently the Pathology resident – Johns Hopkins at the University of Vermont; with fellowships at Yale University, Johns Hopkins (renal pathology), Professor of Anatomic Pathology – The Johns Hopkins University School of Medicine (on faculty since 1983) Her research interests cover acute renal failure, renal pathology and transplant pathology where she holds over 100 peer-reviewed articles.

Her educational activities include teaching of medical students, pathology residents and renal pathology and nephrology fellows. She established and directed an ACGME-accredited program in renal pathology is mentor to 12 fellows and is an invited lecturer for over 100 national and international meetings

She is on the editorial board of JASN and NKF- MD medical board, a member of NIDDK special grants review committee.

Heinz Regele, MD
Austria

He graduated from the University of Vienna in 1989 and was made staff member at the Clinical Institute of Pathology in Vienna in 1991. In 1997 he received his Austrian license for Pathology (Facharzt). He is currently the Associate professor for clinical pathology at the University of Vienna where he has been since 2003

He is active in Renal and transplant pathology since 1993 and the Vienna Renal Biopsy Registry since 1994. His main research interests cover Humoral allograft rejection, Endothelial cells in allograft rejection and Molecular mechanisms in glomerular diseases.
Giuseppe Remuzzi, MD
Italy
Currently he is Professor of Nephrology and Director of the Department of Internal Medicine and Transplantation of the Ospedali Riuniti di Bergamo, Italy and Director of the Division of Nephrology and Dialysis of the same hospital. He also directs the Negri Bergamo Laboratories of the “Mario Negri” Institute for Pharmacological Research, a unique group of basic scientists and clinicians devoted to the study of renal disease, with particular focus on platelet endothelial interactions, vascular prostaglandin biology, coagulation and renal disease, progression of renal disease, experimental models of glomerular damage, and transplant immunology and tolerance. Particularly far-reaching are his contributions to our understanding of the pathophysiology of hemolytic uremic syndrome, prostaglandin metabolism in pregnancy, renal vascular biology in uremia, the role of protein trafficking in renal disease progression, the induction of graft tolerance by intrathymic injection of donor antigens, and the role of the co-stimulatory CD28-B67 pathway in transplant rejection and the prevention of renal and cardiovascular damage in diabetes. Prof. Remuzzi serves on editorial boards of numerous journals including the prestigious New England Journal of Medicine and is member of the International Advisory Board of The Lancet. In recognition of his achievements, he has been awarded in 1998 honorary memberships in the Association of American Physicians and the British Royal Society of Physicians. In 2005 during the World Congress of Nephrology in Singapore he received the ISN Jean Hamburger Award. Prof. Remuzzi has authored and co-authored more than 890 scientific articles, reviews and monographs.

David Rush, MD, FRCPC, FACP, FASN
Canada
Dr. Rush received an MD degree in 1972 from the National University of Tucumán, Argentina. His post-graduate training in Internal Medicine and Nephrology was undertaken at the University of Western Ontario in London. In 1982, he was recruited to the University of Manitoba in Winnipeg. He is currently Professor and Head of the Section of Nephrology at the University of Manitoba and Director of Transplant Manitoba – Adult Kidney Program. His interests are clinico/pathological correlations in acute and chronic renal allograft rejection, non-invasive monitoring of the renal allograft and biomarker development, as well as medical education.

Paul Sweny, MD
UK
Dr. Sweny trained at Downing College Cambridge and then at Guy’s Hospital, London. He did his MD thesis in Animal Models of Nephritis at Guy’s before training in clinical nephrology at the Hammersmith Hospital (Prof Sir Keith Peters). He was appointed as Consultant Nephrologist at the Royal Free Hospital in London in 1979. He has a special interest in the medical management of renal transplant patients. He was instrumental in introducing Basiliximab into clinical practice and has a particular interest in CMV, PTLD and vascular complications of renal transplantation. He has published over 100 peer review articles, two textbooks and edited two further books as well as contributing several chapters to other textbooks.

George Tellides
USA
Dr. George Tellides is Professor of Surgery (Cardiothoracic) at Yale University, Director of Cardiac Transplantation at Yale-New Haven Hospital, and Chief of Cardiothoracic Surgery at the West Haven VA Hospital. He graduated M.B.B.Ch from the University of the Witwatersrand and D.Phil. from the University of Oxford. He completed general surgery residency training at Yale-New Haven Hospital and cardiothoracic surgery residency training at Brigham and Women’s Hospital. His research interest is immune-mediated vascular remodeling.
Armando Torres, MD, PhD  
Spain

Armando Torres is the Clinical Chief of the Nephrology Section, Professor of Medicine and Director of the Research Unit at the University Hospital in Tenerife. He is a member of the Spanish Research Network in renal diseases (RedInRed; Instituto de Salud Carlos III).

His main research areas are: Bone and Mineral Metabolism in Renal Disease; Primary Hyperoxaluria type 1; Cardiovascular and Metabolic complications of renal transplantation. His most recent papers include the following:


Stefan G. Tullius, MD, PhD  
USA

Stefan G. Tullius, MD, PhD, trained and had been on faculty at the Charite University Hospital in Berlin, Germany until 2004 when he became Chief of Transplant Surgery at Brigham and Women’s Hospital in Boston, MA, U.S.A., Associate Professor of Surgery at Harvard Medical School and Principal Investigator of the Transplant Surgery Research Laboratory. He has written > 150 original publications in addition to numerous overview articles and text chapters focusing on the effect of organ quality on transplant outcome and chronic allograft disease. Dr. Tullius is an Associate Editor of Transplant International and is on the Editorial Board of Transplantation. From 2003-2007 he was Council member of the European Society of Organ Transplantation (ESOT) and the founding Chair of the Basic Science Committee of ESOT. He has served on the Int. Advisory group of the World Transplant Congress in Boston 2006 and is on the Scientific Committee of the Basic Science meeting of TTS/ESOT in Brussels 2009.

Flavio Vincenti, MD  
USA

Dr. Vincenti completed his medical training, internship and residency at the American University Medical Center, Beirut, Lebanon. He then did a two-year nephrology fellowship at Emory University School of Medicine. He came to the University of California, San Francisco in July of 1975 for a transplant nephrology fellowship and has been on the staff of the Kidney Transplant Service at UCSF since 1976. He is board certified in internal medicine and nephrology.

Dr. Vincenti is a member of the Immune Tolerance Network. In addition he is an associate editor of Clinical Journal of the American Society of Nephrology and is on the editorial board of Transplantation. Dr. Vincenti is widely published and has authored or co-authored over 170 articles on transplantation. Dr. Vincenti was the primary investigator of an article published in 1978 in the New England Journal of Medicine concerning the important role of blood transfusions in improving the outcome following kidney transplantation. He also reported a series of articles on the complications of transplantation including of aseptic necrosis and recurrent diseases in renal allografts. He has contributed to the understanding of the incidence and risk of recurrence of focal glomerulosclerosis as well as its outcome after transplantation. In the 1990s, Dr. Vincenti has participated in a number of important multicenter clinical trials including studies with OKT3, tacrolimus, daclizumab, basiliximab, HuM291, anti-CD80/86 monoclonal antibodies, efazilumab, anti-CD154 and belatacept. Dr. Vincenti has been the leading investigator and author of several studies on the use of the new anti interleukin 2 receptor monoclonal antibodies. Dr. Vincenti is currently involved in clinical trials with costimulatory blockade in order to establish tolerance. Dr. Vincenti was honored by the National Kidney Foundation of Northern California on May 20, 2000 for his contributions to transplantation and treatment of renal failure. He was the recipient of the AST 2002 Novartis Clinical Science Award.

Dr. Vincenti has been an active member of the American Society of Transplantation and helped establish the clinical trials committee, which he chaired from 2002-2004; he then chaired the development committee from 2004-2006. He has been on board of the American Society of Transplantation since 2003 and currently is serving as its president (2007-2008).